Literature DB >> 14530585

Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.

Deborah Krieger1, Keith Hansen, Colleen McDermott, Roy Matthews, Rachel Mitchell, Natasha Bollegala, Shree Bhalerao.   

Abstract

The use of typical neuroleptics has always been the mainstay of treatment for delirium following traumatic brain injury (TBI). Given the recent application of atypical neuroleptics to various psychiatric conditions formerly treated with typical neuroleptics, one questions whether this new class of drugs is superior to its predecessor in treating delirium post-TBI. We present a case of one patient with TBI-induced delirium where in fact the use of the typical mid-potency neuroleptic, loxapine, appeared to have a better clinical effect over the atypical neuroleptic, olanzapine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530585

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  4 in total

1.  Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

2.  Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options.

Authors:  Joseph D Markowitz; Meera Narasimhan
Journal:  Psychiatry (Edgmont)       Date:  2008-10

3.  Effect of loxapine on electrical brain activity, intracranial pressure, and middle cerebral artery flow velocity in traumatic brain-injured patients.

Authors:  Thomas Lescot; Ana Rosa Pereira; Lamine Abdennour; Paola Sanchez-Pena; Lionel Naccache; Pierre Coriat; Louis Puybasset
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 4.  Current and Potential Pharmacologic Therapies for Traumatic Brain Injury.

Authors:  Jowy Tani; Ya-Ting Wen; Chaur-Jong Hu; Jia-Ying Sung
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.